We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other UK growth stocks.

The start of this year has marked interesting developments for the UK market. The main stock market index has increased 5.86% since the beginning of 2025, and despite global economic uncertainties, UK equities are trading at significant discounts compared to their US counterparts. The valuation gap suggests potential opportunities for growth-seeking investors.

Reflecting on the 2024 market, economic uncertainties and fluctuations were dominating factors, which required investors to examine stock performances more closely. Interestingly, smaller companies performed the best in the UK market, delivering returns of 13.78%, while the larger companies were close behind, with a return of 9.66%. In an unpredictable environment, high institutional and hedge fund ownership in growth companies indicates strong investor confidence, which could mean potential for long-term value creation.

Growth stocks are stocks that tend to outperform the broader market. They are company stocks that are likely to grow at a significantly higher rate than the average growth for the market. These companies often reinvest their profits to fuel further growth rather than paying dividends. Investors are typically attracted to growth stocks due to the potential for attractive capital appreciation over time. More often, these are smaller stocks or startups that gain a sudden uptick due to the industry or tech push.

Growth Stocks Vs Value Stocks

Growth stocks are typically priced higher relative to current earnings due to anticipated future growth. They typically trade at a high price-to-earnings (P/E) ratio. Compared to them, value stocks are priced lower relative to their fundamentals and are seen as undervalued in the market. While growth stocks tend to operate in dynamic industries such as tech, value companies may be in more established industries and offer dividends. In 2024, value investing slightly outperformed growth in the UK, which necessitates the need to create a diversified investment approach.

Identifying Growth Stocks

While most growth stocks are small companies with market potential, they can also be larger firms where the company has a growth mindset and its share values continue to rise. There are still some common traits that all growth stocks share. The foremost characteristic is the company’s constant stronger financial performance compared to its peers. If the company is growing at a percentage higher than the average growth of the market, it has growth potential better than its peers. Secondly, growth stocks are typically companies that have a stronger or unique product line with a loyal customer base. They have investments in technology to build an edge over competitors. With a strong focus on innovation, they ensure they are ahead in the race to capture greater market shares in their industry. They might also be companies that have high potential to grow in the future, perhaps through a market build-up, expecting to reach key milestones in the future.

While these shares can have high potential and, thus, be attractive to investors, they can also be high-risk, with stock expectations going south.

In the current market scenario, growth stocks offer several advantages. Primarily, there is the potential for significant increases in stock value as companies expand. Growth stocks can act as a hedge against inflation, as companies with strong growth can outrun inflation. Positive outlooks and focus on innovative sectors can also accumulate investor interest and elevate stock prices. It is, however, key to consider the inherent risks to avoid drastic declines.

Our Methodology

To compile our list of the 10 best UK growth stocks to buy now, we screened the 20 largest companies in the UK in growth-related industries. We then ranked our choices by revenue growth potential and hedge fund sentiments.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points. (see more details here).

A laboratory technician carefully studying a microscope with a biopharmaceutical product inside.

Autolus Therapeutics plc (NASDAQ:AUTL)

Revenue growth past 5 years: 190.29%

Number of hedge fund holders: 20

Autolus Therapeutics plc (NASDAQ:AUTL) is a UK-based clinical-stage biopharmaceutical company that focuses on the development of next-generation T-cell therapies for the treatment of cancer and autoimmune diseases. The company leverages advanced cell programming and manufacturing technologies to provide innovative solutions in the field of immuno-oncology.

Autolus Therapeutics plc (NASDAQ:AUTL) achieved a breakthrough milestone in November 2024 with the U.S. Food and Drug Administration's approval of Aucatzyl, a CAR-T cell therapy designed to treat acute lymphoblastic leukemia (ALL). This therapy is significant for its unique mechanism that binds to cancer cells for a shorter duration and can potentially reduce severe side effects associated with earlier CAR-T treatments. With the therapy demonstrating promising clinical outcomes, the company anticipates robust demand for Aucatzyl as a strong competitor against existing treatments.

As the global biotechnology sector is rapidly expanding, with market size projected to grow from $483 billion in 2024 to $546 billion by 2025, Autolus Therapeutics plc (NASDAQ:AUTL) is positioned to benefit from a burgeoning industry. The expansion is driven by breakthroughs in biopharmaceuticals, increased FDA drug approvals, and a boost in life sciences research. Autolus’  focus on cutting-edge CAR-T cell therapies aligns with the sector's trajectory towards innovative cancer treatments.

With the successful commercialization of Aucatzyl, the company is expected to scale up its revenue, with projections estimating an exponential increase from $50.2 million in 2025 to $972 million by 2030. Autolus is also exploring the application of its CAR-T cell technology in treating autoimmune diseases, potentially opening new revenue streams and expanding its therapeutic portfolio.

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best UK growth stocks to buy in the biotechnology industry. Together with an innovative approach to CAR-T cell therapy, strategic financial backing, and a clear roadmap for future developments, the company is awaiting to be launched into a growth upswing. With the global demand for advanced cancer treatments on the rise, Autolus is well-equipped to capitalize on emerging opportunities.

Overall AUTL ranks 8th on our list of the best UK growth stocks to buy. While we acknowledge the potential for AUTL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AUTL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stock To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap. 

 

Disclosure: None. This article is originally published at Insider Monkey.